Amrize AG heads into its October 26 earnings print with an unusual dynamic: insiders are buying aggressively while the stock slides further from the price they paid.
The insider story here is the standout. Chairman and CEO Jan Philipp Jenisch made multiple open-market purchases on September 2, accumulating 30,000 shares across four transactions at prices around CHF 42.40–42.53. None were executed under a pre-arranged 10b5-1 plan — these were discretionary buys. Combined with purchases from director Jacques Wolf Sanche (4,150 shares), Chief Legal Officer Denise Singleton (3,500 shares), and Chief Strategy Officer Samuel Poletti (2,510 shares), the executive team has collectively bought roughly CHF 2.6 million worth of stock in the past 90 days. That cluster of buying from across the C-suite, all at prices well above where the stock trades today, reflects a level of internal conviction worth noting — even if the market has not yet agreed.
The problem is the price action. Amrize has fallen 12.8% over the past month to CHF 31.84 — a meaningful discount to the ~CHF 42–47 range where insiders were buying. The stock gave back 0.7% on the week, clawing back just over 1% on Tuesday but unable to sustain any momentum. The peer group fared better: closely correlated HOLN was roughly flat on the week, while Vienna-listed gained over 3%. The underperformance is not new — Amrize trailed European building materials peers through the summer, and the ORTEX composite score flags persistent momentum weakness, with relative strength negative across the 91-, 182-, and 365-day windows.
The borrow market tells a different story from the price action — and for once it is a reassuring one. Availability is extremely loose, running at roughly 2,476% of current short interest. That means for every share already borrowed to short, there are about 25 more available. Short interest barely registers at well under 1% of the free float, and borrowing costs are a low 0.66% — up about 12% on the week but still negligible in absolute terms. The ORTEX short score of 29.2 sits in the bottom third of the universe. There is no meaningful short-side pressure here; the selloff is not driven by bears piling in.
The activist register adds one genuinely newsworthy wrinkle. Thomas Schmidheiny filed a Schedule 13D on Amrize in June 2025 — a form that signals active rather than passive intent — with a 6.67% stake as last disclosed. A 13D on the register means at least one large holder has declared it may seek influence over the company's direction. Separately, BlackRock has trimmed from 6.9% to 3.6% as last reported in January, and The Vanguard Group filed a 13G/A in March 2026 disclosing a position that had fallen to zero from 5.3% previously. As the disclosure note makes clear, these stakes reflect positions around the 5% reporting threshold and may have shifted further since filing. Still, the combination of a 13D activist, a CEO buying at prices 30% above current levels, and a broader exodus by passive index giants paints a complicated ownership picture heading into Q3 results.
Valuation has re-rated downward with the stock. The price-to-earnings multiple has compressed by roughly 1.9 turns over the past 30 days to 13.5x, and price-to-book has fallen 0.21 turns to 1.46x. EV/EBITDA ticked up slightly to 7.8x. The company's earnings history offers a sobering reference point: the last print on August 7 sent the stock down nearly 10% in a single session, with the five-day loss also approaching 9.5%. The results before that produced a similar double-digit drop. A pattern of sharp post-earnings selloffs, combined with a stock already down over 12% in a month, frames October 26 as the moment to watch — not just for whether results beat, but for whether any guidance shift is enough to arrest the slide that insiders have been buying into all the way down.
See the live data behind this article on ORTEX.
Open AMRZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
